Drugs / ladostigil
ladostigil
also known as
ladostigil hemitartrate · LADOSTIGIL TARTRATE · Ladostigilo · TV-3326 · TV-3326 FREE BASE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01429623 | Feb 2012 → Jul 2016 | cognitive impairment with or without cerebellar ataxia, dementia | Avraham Pharmaceuticals Ltd | Completed | Missed primary |
| Phase 2 | NCT01354691 | Feb 2011 → Sep 2012 | Alzheimer disease, amnestic disorder | Avraham Pharmaceuticals Ltd | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ladostigil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01354691 ↗ |
| Known as | ladostigil hemitartrate | “Drug: ladostigil hemitartrate” NCT01354691 ↗ |
| Known as | LADOSTIGIL TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL255231 ↗ |
| Known as | Ladostigilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL255231 ↗ |
| Known as | TV-3326 | ChEMBL registry synonym — accepted as the source's own label CHEMBL255231 ↗ |
| Known as | TV-3326 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL255231 ↗ |
| Modality | Small molecule | — CHEMBL255231 ↗ |
| Route | Oral | “Oral, solid dosage.” NCT01354691 ↗ |